Centessa Pharmaceuticals plc American Depositary Shares (CNTA) is a publicly traded Healthcare sector company. As of May 20, 2026, CNTA trades at $39.55 with a market cap of $6.13B and a P/E ratio of -27.22. CNTA moved +0.18% today. Year to date, CNTA is +72.68%; over the trailing twelve months it is +201.14%. Its 52-week range spans $9.60 to $40.26. Analyst consensus is neutral with an average price target of $42.40. Rallies surfaces CNTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Law Firm Challenges Centessa $38 Cash Plus Up to $9 CVR Sale to Lilly: Centessa Pharmaceuticals shareholders will receive $38 in cash per share plus one non-transferrable contingent value right for up to an additional $9 based on milestone achievements in its sale to Eli Lilly. Halper Sadeh LLC is investigating potential fiduciary duty breaches and deal terms that may restrict competing offers.
| Metric | Value |
|---|---|
| Price | $39.55 |
| Market Cap | $6.13B |
| P/E Ratio | -27.22 |
| EPS | $-1.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.26 |
| 52-Week Low | $9.60 |
| Volume | 814.63K |
| Avg Volume | 0 |
| Revenue (TTM) | $15.00M |
| Net Income | $-197.53M |
| Gross Margin | 0.00% |
10 analysts cover CNTA: 0 strong buy, 1 buy, 9 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $42.40.